Table 1.
Comparative effects of simulated robust optimization uncertainties in proton beam range and setup on dosimetry in a prostate intensity-modulated proton therapy (IMPT) planning system.
| Clinical Scenarios | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Range uncertainty | 3.5% | 3.0% | 2.5% | 2.0% | 1.5% | 1.0% | |||
| Setup error | 5 mm | 3 mm | 2 mm | 1 mm | 1 mm | ||||
| CTV, V78Gy | 99.9% | 99.6% | 99.1% | 98.4% | 98.8% | 98.5% | 98.8% | 99.3% | 99.6% |
| Rectum, V70Gy | 30.8% | 25.9% | 24.5% | 20.1% | 19.7% | 20.1% | 18.2% | 19.5% | 19.5% |
| Bladder, V70Gy | 35.2% | 30.6% | 29.1% | 25.3% | 24.7% | 24.7% | 24.5% | 23.6% | 23.5% |
| Rectum, Dmean (Gy) | 37.1 | 33.3 | 32.4 | 28.8 | 28.5 | 28.9 | 27.1 | 28.4 | 28.5 |
| Bladder, Dmean (Gy) | 40.4 | 37.0 | 36.1 | 32.8 | 32.3 | 32.5 | 32.2 | 31.8 | 31.7 |
| Non-target tissue, Dmean (Gy) | 14.6 | 13.6 | 13.3 | 12.3 | 12.1 | 12.1 | 11.7 | 11.8 | 11.7 |
Non-target tissue describes body tissue that excludes the clinical target volume (CTV) and limits the region between 1 cm superior and inferior from the CTV.